3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neuroblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Bacterial Infections
1
Agammaglobulinemia
1
Interventions
Rituximab
49
Cyclophosphamide
28
venetoclax
24
Bendamustine Hydrochloride
24
obinutuzumab
22
ibrutinib
21
Chlorambucil
20
fludarabine
16
fludarabine phosphate
15
idelalisib
13
acalabrutinib
11
pirtobrutinib
7
ofatumumab
7
zanubrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Cyclosporine
5
Radiotherapy
4
Prednisone
4
Doxorubicin
4
duvelisib
3
Whole-Body Irradiation
3
Specimen Handling
3
Methotrexate
3
Lenalidomide
3
Filgrastim
3
Epoetin Alfa
3
Cyclosporins
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
gamma-Globulins
×
Clear all
NCT05645107
2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3
Recruiting
386 enrolled